



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	April 21, 2011 January 5, 2011; June 6, 2012; July 13, 2012; July 25, 2012, July 30, 2014, June 05, 2015

NUEDEXTA® (dextromethorphan and quinidine sulfate) capsule

LENGTH OF AUTHORIZATION: UP TO SIX MONTHS

REVIEW CRITERIA:

INITIATION OF THERAPY:

- Patient must be ≥ 18 years old.
- Must have a diagnosis of Pseudobulbar affect (PBA) secondary to a neurologic disorder (eg. ALS, MS, Parkinson's disease, a stroke, traumatic brain injury...).
- Documentation of the secondary neurologic disorder must be submitted
- Must be prescribed or recommended by a specialist (**If prescriber is not a specialist then the referral notes of the specialist must be submitted.**)

CONTINUATION OF THERAPY (applies only after an initial authorization has been made by Florida Medicaid):

- Patient must be ≥ 18 years old.
- Must have a diagnosis of Pseudobulbar affect (PBA) related to a neurologic disorder (eg. ALS, MS, Parkinson's disease, a stroke, traumatic brain injury...).
- Progress notes or medical records must demonstrate effectiveness of therapy

DOSING:

Starting dose: One capsule daily by mouth for 7 days.

Maintenance dose: After 7 days, 1 capsule every 12 hours.